Growth Hormone Treatment on Phosphocreatine Recovery in Obesity

Overview

Obesity is associated with reduced growth hormone (GH) secretion. Reduced GH secretion in obesity is associated with increased cardiovascular disease risk. However, it is not yet known how reduced GH increases cardiovascular disease risk in obesity. The investigators hypothesize that reduced GH contributes to dysfunction of the mitochondria. Therefore, the investigators hypothesize that treatment of obese subjects with reduced GH secretion with GH will improve mitochondrial function and that this improvement in mitochondrial function will contribute, in part, to the effects of GH to improve metabolic parameters in obesity. The investigators propose to study skeletal muscle mitochondria in obese subjects with reduced GH secretion using magnetic resonance spectroscopy and muscle biopsies before and after treatment with GH.

Full Title of Study: “The Effects of Short Term Growth Hormone Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2013

Interventions

  • Drug: Growth hormone treatment
    • Growth hormone 0.4 mg once daily (titrated to IGF-1) by sub-cutaneous injection for 12 weeks.

Arms, Groups and Cohorts

  • Experimental: Growth Hormone

Clinical Trial Outcome Measures

Primary Measures

  • Phosphocreatine Recovery
    • Time Frame: 12-weeks
    • The primary objective of this study is to determine the effects of growth hormone on mitochondrial function as assessed by 31P-MRS in obese subjects with reduced GH secretion. Mitochondrial function was represented by ViPCr, a measure of phosphocreatine recovery after sub-maximal exercise. Univariate regression analyses was performed to assess the relationship between the change in skeletal muscle IGF-1 mRNA after 12 weeks treatment with rhGH to change in ViPCr.

Secondary Measures

  • Change in Circulating IGF-1 Concentration
    • Time Frame: Baseline and 12-weeks
    • Change in circulating IGF-1 from Baseline to 12-weeks is reported.
  • Change in Skeletal Muscle IGF-1 Gene Expression
    • Time Frame: Baseline and 12-weeks
    • Change in skeletal muscle IGF-1 gene mRNA expression from Baseline to 12-weeks is reported.
  • Change in Body Composition
    • Time Frame: Baseline and 12-weeks
    • Change in waist circumference from Baseline to 12-weeks is reported.
  • Change in Inflammatory Marker
    • Time Frame: Baseline and 12-weeks
    • Change in high sensitivity C-reactive protein (hsCRP) from Baseline to 12-weeks is reported.
  • Change in Insulin Sensitivity
    • Time Frame: Baseline and 12-weeks
    • Change in fasting glucose from Baseline to 12-weeks is reported.
  • Change in Phosphocreatine Recovery
    • Time Frame: Baseline and 12-weeks
    • Change in phosphocreatine recovery, represented by ViPCr, from Baseline to 12-weeks is reported.

Participating in This Clinical Trial

Inclusion Criteria

1. Men age 18-60 years old 2. BMI ≥ 30 kg/m2 3. Waist circumference ≥ 102 cm 4. Peak GH value of ≤ 4.2 μg/l on standard GHRH-arginine stimulation test Exclusion Criteria:

1. Obesity due to a known secondary cause (Cushing's syndrome, hypothyroidism, etc) or a history of gastric bypass procedure. 2. Subjects who have a known history of diabetes, fasting blood sugar >125 mg/dl or using any anti-diabetic drugs. 3. Use of Aspirin, Clopidogrel (Plavix), Warfarin (Coumadin) or other anti-coagulants 4. Subjects on testosterone, glucocorticoids, anabolic steroids, GHRH, GH or IGF-1 within 3 months of enrollment. 5. Changes in lipid lowering or anti-hypertensive regimen within 3 months of screening 6. History of pituitary tumor, hypopituitarism, pituitary surgery, pituitary/brain radiation or traumatic brain injury or any other condition known to affect the GH axis. 7. Severe chronic illness including HIV, active malignancy or history of colon cancer. 8. Hemoglobin < 9.0 g/dL, SGOT > 2.5 x upper limit normal, Creatinine >1.5 mg/dL, or PSA >5 ng/ml. 9. Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit. 10. Any condition judged by the patient's physician to cause this clinical trial to be detrimental to the patient. 11. Contraindications to MRI scanning.

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Massachusetts General Hospital
  • Collaborator
    • Pfizer
  • Provider of Information About this Clinical Study
    • Principal Investigator: Hideo Makimura, Principal Investigator – Massachusetts General Hospital
  • Overall Official(s)
    • Hideo Makimura, MD, PhD, Principal Investigator, Massachusetts General Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.